Viatris Q3 2026 Results: Net Loss $325 Million on Revenue of $3.75 Billion
- US stocks
- Earnings
- Health Care

Viatris (Nasdaq: VTRS) reported GAAP total revenues of $3.75 billion and a GAAP net loss of $325.3 million for the third-quarter 2026 period, and it said on 5 Nov 2026 that it had raised the midpoints of its 2026 guidance. GAAP diluted loss per share was $0.28; the company's adjusted EPS, a company-defined measure, was $0.71 per share.
Key highlights
- Revenue (GAAP): $3.75 billion, down 0.3% YoY and up 0.1% QoQ
- Net loss (GAAP): $325.3 million, against $128.2 million a year earlier
- Diluted loss per share (GAAP): $0.28, against $0.11 a year earlier
- Adjusted EPS (company-defined): $0.71 per share, up 6% on a reported basis
Summary
| Particulars | Q3 2026 | Q3 2025 | YoY | Q2 2026 | QoQ |
|---|---|---|---|---|---|
| Revenue | 3,749.5 | 3,759.9 | -0.3% | 3,745.9 | +0.1% |
| 261.5 | 178.8 | +46.3% | n/a | n/a | |
| Operating margin | 6.97% | 4.76% | +2.21 pp | n/a | n/a |
| -325.3 | -128.2 | -153.7% | n/a | n/a | |
| Net income margin | -8.68% | -3.41% | -5.27 pp | n/a | n/a |
| Diluted EPS ($) | -0.28 | -0.11 | -154.5% | n/a | n/a |
Figures are in $ million except EPS; YoY compares with Q3 2025 and QoQ with Q2 2026. Q3 2026 is the three months to 30 Sep 2026, from the company's release. Earlier quarters are checked against the company's SEC XBRL filings. GAAP; net income attributable to the company; diluted EPS. Changes and margins computed by Blacklitt.
The table shows GAAP revenue of $3,749.5 million, down 0.3% from $3,759.9 million a year earlier and up 0.1% from the previous quarter. GAAP operating income was $261.5 million against $178.8 million, and the operating margin rose to 7.0% from 4.8%, or 2.2 percentage points higher.
GAAP net loss was $325.3 million, a margin of -8.7% against -3.4%. The company attributes the loss mainly to a $453.2 million income tax provision, which it says arose from losses in jurisdictions where minimal benefit can be realized.
Adjusted figures exclude purchase accounting amortization and restructuring costs
Adjusted net earnings, a company-defined measure, were $821.4 million, against $784.3 million a year earlier, after adding back items such as purchase accounting amortization of $613.7 million and restructuring costs of $66.2 million.
Nashik plant production is suspended pending remediation
The company said the FDA classified the Nashik, India oral solid dose facility as Official Action Indicated in September, after 483 observations issued in May. In October it voluntarily suspended manufacturing there to focus on remediation, and it expects to resume production in the first quarter of 2027.
The company estimates supply constraints reduced third-quarter total revenues by about $100 million and expects about $100 million of impact in the fourth quarter.
Guidance midpoints raised, and $717 million returned to shareholders
The company now expects 2026 total revenues of $14,700 million to $14,900 million, against $14,550 million to $14,950 million previously; adjusted EBITDA of $4,450 million to $4,550 million, against $4,300 million to $4,500 million; and adjusted EPS of $2.56 to $2.63 per share, against $2.45 to $2.59.
The company said it returned about $717 million to shareholders through 30 Sep 2026, including about $300 million through share repurchases, and that about $700 million remains under its board-authorized program.
The company agreed to acquire Pacira BioSciences for $36.50 per share in cash, an aggregate equity value of $1.65 billion, with closing expected by the end of November 2026.
Inference
The weighted average diluted share count was 1,148.6 million in the quarter, against 1,164.6 million a year earlier.
The release does not give full-year GAAP net income or GAAP EPS guidance, which the company says it does not provide, or Pacira's contribution to 2026 results. Next dated steps are the Pacira closing expected by the end of November 2026 and the expected Nashik production resumption in the first quarter of 2027.
Filed with the US SEC on . Reference: Original filing (SEC)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.

